FXR agonist obeticholic acid and engineered FGF19 analog NGM282 have been shown to improve non-alcoholic steatohepatitis (NASH) in clinical trials7,8. This evidence concerns the gene FGF19 and metabolic dysfunction-associated steatohepatitis.